Last reviewed · How we verify
Benralizumab Prefilled Syringe
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.
Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | Benralizumab Prefilled Syringe |
|---|---|
| Also known as | Transcriptomic |
| Sponsor | Nantes University Hospital |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5 receptor alpha (IL-5Rα) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
Benralizumab targets interleukin-5 receptor alpha (IL-5Rα), a key receptor expressed on eosinophils and basophils. By blocking this receptor, the drug prevents IL-5 signaling and promotes antibody-dependent cellular cytotoxicity (ADCC), resulting in rapid depletion of these cells. This mechanism effectively reduces eosinophilic inflammation in conditions like severe eosinophilic asthma.
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Injection site reactions
- Pyrexia
Key clinical trials
- Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics (PHASE4)
- A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (PHASE3)
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype (PHASE3)
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (PHASE3)
- Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis (PHASE3)
- Predictive Signature of Benralizumab Response (PHASE4)
- Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benralizumab Prefilled Syringe CI brief — competitive landscape report
- Benralizumab Prefilled Syringe updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI